TMCnet News
BioSTL Builds Gateway for U.K.'s National Health Service Innovators with St. Louis as Launch Point into U.S. MarketNew agreement with one of the world's top public health systems designed to boost local deal flow, affirms St. Louis as a preferred destination for AI and digital health innovators ST. LOUIS, June 15, 2026 /PRNewswire/ -- BioSTL Global, the international arm of BioSTL, the backbone of the region's bio-innovation ecosystem, has reached an agreement with the innovation network commissioned by the U.K.'s National Health Service (NHS) that promises to attract new companies to St. Louis' nationally recognized healthcare industry. The new collaboration is with the NHS's Health Innovation Networks (HINs) in South London, Kent, Surrey, Sussex and Yorkshire-Humber, where specific needs for innovative new solutions are identified and pursued for the 55-million-patient centralized healthcare system. Under the agreement, U.K. startups and scaleups in digital healthcare innovation affiliated with HINs that want to enter the U.S. market will gain a soft landing in St. Louis. The area is home not only to a vibrant healthcare-innovation community, but also to a $500 billion healthcare sector of providers, payers and pharmacy benefit managers—potential partners for pilots, purchase deals, licensing, or commercial scaling for new AI and digital health technology. BioSTL Global has built a St. Louis-based comprehensive soft-landing program for global healthcare innovators looking to enter and scale the complex U.S. market. The program includes the Global Innovation Advisory, the Global Health Innovation Summit, the Center for Rural Health Innovation and the Healthcare AI Collaborative. "We are well positioned to connect promising U.K. AI and digital health startups to our massive ecosystem of hospitals, insurance and health-services companies headquartered in St. Louis," said Vijay Chauhan, BioSTL Global Lead. "Not only do we offer a range of specialized programs, but also participation at our annual BioSTL Global Health Innovation Summit, where decision makers from the St. Louis and Midwest healthcare sector meet with startups who are addressing their specific needs," he said. Since 2014, the program has attracted 79 companies from 10 countries and generated 155 contracts totaling $750 million—ranging from product purchases and pilot programs to new local offices, clinical trials, and investment. A BioSTL delegation led by Chauhan recently returned from London, York, Manchester and Warwick, where Chauhan signed a memorandum of understanding with local HIN leaders. The group also met with their U.K. counterparts and new companies interested in the move, and participated in the U.K.'s biggest healthcare-innovation conference, NHS ConFed Expo. The delegation included health innovation leaders from Mercy, Washington University in St. Louis, and the healthcare-AI industry. Chauhan is available for interviews upon request. "I am delighted with BioSTL's partnership ith leading Health Innovation Networks," said Madhukar Bose, head of Digital Health for the U.K.'s Department of Business and Trade. Bose called BioSTL's approach and capabilities "unique and best-in-class," adding, "The collaboration will undoubtedly create opportunities for innovators in England and St Louis to solve the pressing health challenges our respective health systems face." U.K. startups that participate will gain the opportunity to engage in the healthcare marketplace in a number of ways, including through BioSTL's Center for Rural Health Innovation and Healthcare AI Collaborative. The programs connect rural healthcare providers in the greater region with innovators addressing their specific needs, including for responsible AI and remote patient monitoring and management tools. "One of the reasons St. Louis is a center of excellence for digital healthcare innovation is our location in the middle of the Midwest, among states that, like our own, have populations that suffer disproportionately high rates of chronic health conditions including cardiovascular disease, diabetes, COPD, and cancer," Chauhan said. "This creates strong demand for scalable, technology-enabled solutions that improve access, monitoring, and positive outcomes for rural and urban patients alike—the definition of digital, patient-centered healthcare," he said. BioSTL Delegation Members: Vijay Chauhan, BioSTL Global Lead Patrick Aguilar, M.D. Damon Broyles, M.D., FAAFP Krischa Winright Noah Wolthausen, MPH Contact: About BioSTL Global About BioSTL About Health Innovation Networks
SOURCE BioSTL 
|
View original content to download multimedia: